10× more potent than NMN: the longevity compound that's changing how scientists think about NAD+ boosting

The NMN era and its limitations

NMN (nicotinamide mononucleotide) emerged as the dominant NAD+ precursor in the longevity supplement space after David Sinclair's research at Harvard highlighted its potential in animal models. Human trials followed, showing meaningful increases in blood NAD+ levels and improvements in energy and metabolic markers at doses of 500mg–1g daily. But NMN has limitations: it requires enzymatic conversion before entering cells, its bioavailability is affected by digestive conditions, and at high doses, it can produce tolerance effects that reduce its efficacy over time. Researchers looking for more efficient NAD+ activation have been investigating alternative pathways.

TND1128: a different mechanism

TND1128 (5-deazaflavin) is a patented derivative of vitamin B2 that targets the same mitochondrial energy activation pathways as NMN, but works through a distinct biochemical route. Rather than acting purely as a NAD+ precursor, TND1128 appears to directly activate NAD+-dependent enzymes including sirtuins (SIRT1 and SIRT3), which regulate mitochondrial biogenesis, DNA repair, and metabolic efficiency. The claimed 10× potency advantage refers to the dose required to achieve equivalent enzymatic activation — meaning the active compound reaches its target more efficiently at lower concentrations.

Liposomal delivery: solving the absorption problem

Aeternum's TND1128 100mg capsules use liposomal nano-delivery technology — the same encapsulation approach used in pharmaceutical drug delivery — which wraps the active compound in lipid spheres that protect it during digestion and facilitate direct absorption through intestinal cell membranes. This increases small intestinal absorption by more than 10× compared to standard oral delivery, which matters because many supplement actives are partially degraded before they can be absorbed. Each capsule provides 100mg of pure TND1128, vegan, acid-resistant, GMP-certified, and third-party tested.

Who is TND1128 most relevant for

TND1128 is positioned as a next-generation option for people who have already explored NMN and are looking for a more potent or more efficient approach to NAD+ pathway activation. It's also relevant for those who find standard NMN doses insufficient or who experience tolerance over time. As a newer compound, the human research is less extensive than for NMN — which is worth noting — but the mechanistic rationale is strong, and the animal model data is compelling. Early adopters in the longevity space tend to be experienced supplement users who monitor their own biomarkers and are comfortable working with emerging compounds.

What to watch for

The longevity supplement landscape is moving quickly, and TND1128 represents the leading edge of that movement. As with any early-stage compound, the evidence base will develop over the coming years. What the current science supports is the mechanistic logic: targeting sirtuin activation directly, with enhanced delivery efficiency, addresses the core limitation of first-generation NAD+ precursors. Whether this translates to meaningfully superior outcomes in practice is a question that rigorous human trials are beginning to answer.